John Connolly speaks on an Endpoints News panel at the 2018 BIIS PharmCube/Endpoints conference in Shanghai (File photo)
July 24, 2020 06:27 AM EDT
People
Peer Review

Turn­ing can­cer in­to a cur­able dis­ease: Im­munother­a­py ex­pert John Con­nol­ly picks up the reins as the new CSO of Sean Park­er’s can­cer in­sti­tute

John Carroll

Editor & Founder

John Con­nol­ly synced with the folks at the Park­er In­sti­tute for Can­cer Im­munother­a­py ear­ly on.

As the sci­ence chief at Sin­ga­pore-based Tes­sa Ther­a­peu­tics, he …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times